Kisqali vs Imbruvica
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Kisqali | US Imbruvica | |
|---|---|---|
| Generic name | ribociclib | ibrutinib |
| Drug class | CDK4/6 Inhibitor | BTK Inhibitor |
| Treats | HR-positive, HER2-negative breast cancer | Chronic lymphocytic leukemia and other blood cancers |
| Category | Oncology | Oncology |
| Manufacturer | Novartis | AbbVie/Janssen |
| Year approved | 2017 | 2013 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $80M | — |
| Common side effects | Low white blood cells, Nausea, Fatigue, Heart rhythm changes (QT) | Bleeding and bruising, Irregular heartbeat (atrial fibrillation), High blood pressure, Infections |
Imbruvica
Frequently asked questions
Is Kisqali or Imbruvica better?
Neither is universally "better." Kisqali (ribociclib) and Imbruvica (ibrutinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Kisqali and Imbruvica?
Kisqali is a CDK4/6 Inhibitor made by Novartis, while Imbruvica is a BTK Inhibitor made by AbbVie/Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Kisqali has the larger estimated TV advertising budget of the two.